Skip to main content

29-07-2019 | Rheumatology | News


FDA gives nod to adalimumab-bwwd

medwireNews: The US FDA has approved adalimumab-bwwd, an adalimumab biosimilar, for the same indications as the reference product.

These indications comprise rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis, in addition to plaque psoriasis and inflammatory bowel disease.

Adalimumab-bwwd will be available as a 40 mg solution in a prefilled autoinjector. The label carries the same boxed warnings as the originator, advising caution regarding the risk for serious infection and malignancy.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group

See also:

See the research in context now

with trial summaries, expert opinion and congress coverage

Image Credits